SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (2680)10/13/2011 6:53:35 PM
From: tnsaf  Read Replies (1) | Respond to of 3202
 
<<Someone on Drew's board pointed out that the author of that letter was the guy who ran the YMI trial at Mayo. Don't know what that means if anything.>>

From their ICMJE disclosure forms, all three authors of the letter have been co-investigators in CYT387 trials as well as multiple ruxolitinib trials and trials of JAK inhibitors by other companies.

Jason